Sign in to continue:

Thursday, April 16th, 2026

Katapult Holdings, Inc. Files 8-K Current Report with SEC on April 15, 2026

Katapult Holdings, Inc. Files Form 8-K: Tenth Limited Waiver Agreement Disclosed

Key Developments:

  • Katapult Holdings, Inc. (NASDAQ: KPLT) has filed a Form 8-K Current Report with the SEC dated April 15, 2026, announcing the execution of a Tenth Limited Waiver agreement.
  • The Tenth Limited Waiver is incorporated as Exhibit 10.1 in the filing and is referenced as a material agreement affecting the company.
  • The waiver involves Katapult Holdings, Inc., its subsidiaries (including Katapult Group, Inc.), and certain lenders, notably Blue Owl Asset Income Fund IV LP, Blue Owl Asset Income Fund (Cayman) IV LP, Blue Owl Asset Income Fund V LP, and Blue Owl Asset Income Fund (Cayman) V LP.

What Investors Need to Know:

  • The Tenth Limited Waiver relates to the company’s credit agreement with its lenders. While the full text of the waiver is incorporated by reference, the excerpt emphasizes that the waiver is “voluntarily and knowingly” executed by Katapult and its affiliates, releasing certain claims in favor of the lenders.
  • Signatories of the waiver include CEO Orlando Zayas for Katapult and David Aidi as Authorized Signatory for the Blue Owl Asset Income Funds, indicating high-level engagement and consent from both management and institutional lenders.
  • Katapult’s common stock (trading symbol: KPLT) and redeemable warrants (trading symbol: KPLTW) remain listed on the Nasdaq Stock Market.
  • The filing affirms that Katapult is not an emerging growth company under SEC definitions, which affects its reporting and disclosure obligations.

Potential Price-Sensitive Information:

  • Execution of the Tenth Limited Waiver may indicate ongoing negotiations or restructuring of financial obligations between Katapult and its primary lenders. This could be interpreted by the market as either a sign of underlying financial stress or proactive management of balance sheet risks, depending on the full details of the waiver and the company’s financial health.
  • The waiver includes a release provision where Katapult and its affiliates waive certain claims against the lenders. Such releases are typically associated with amendments or forbearances in credit agreements, which can have significant implications for the company’s liquidity, capital structure, or risk profile.
  • The lack of any box checked for Written Communications, Soliciting Material, or Pre-Commencement Tender Offers suggests that the filing is not related to a merger, acquisition, or public solicitation event at this time.

Other Shareholder-Relevant Details:

  • No change in the company’s name or address was reported.
  • The company remains subject to SEC reporting requirements as a Nasdaq-listed issuer.
  • No new securities or registration statements were announced in this filing.

Conclusion for Investors:

The Tenth Limited Waiver appears to be a significant event for Katapult Holdings, Inc., as it directly impacts the company’s relationship with its senior lenders. Such waivers typically address covenant breaches or provide temporary relief from certain debt agreement terms, which can be both a risk and an opportunity. Investors should review the full text of the waiver, monitor any subsequent company disclosures, and consider the implications for Katapult’s financial flexibility, cost of capital, and ongoing operations. Any material changes to the credit agreements or company’s ability to comply with debt covenants could have a direct impact on the company’s share price.



Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full SEC filing and consult with their financial advisors before making any investment decisions. The information provided is based on public filings and may not reflect all current or future developments at Katapult Holdings, Inc.


View Katapult Holdings, Inc. Historical chart here



Theriva Biologics Receives FDA Agreement to Advance VCN-01 to Phase 3 Trial for Metastatic Pancreatic Cancer 1

Theriva Biologics Receives Positive FDA Feedback to Advance ...

Interpace Biosciences 2025 Annual Report: Molecular Diagnostics, Business Strategy, and Key Risks

Interpace Biosciences 2025 Annual Report – Key Investor Insi...

   Ad